Top Page
Peijia Medical Ltd.
(9996)
Peijia Medical Ltd. (9996) vs. iShares MSCI Hong Kong ETF (EWH)
Peijia Medical Ltd. Business Overview & Revenue Model
Peijia Medical Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 667.66M | 615.48M | 441.13M | 250.83M | 136.53M | 38.66M |
| Gross Profit | 462.38M | 433.62M | 325.37M | 176.20M | 95.65M | 25.22M |
| EBITDA | -167.28M | -176.59M | -348.52M | -359.90M | -546.54M | -190.87M |
| Net Income | -225.18M | -226.58M | -392.52M | -407.81M | -574.22M | -2.07B |
Balance Sheet | ||||||
| Total Assets | 2.60B | 2.69B | 2.67B | 3.32B | 3.16B | 2.88B |
| Cash, Cash Equivalents and Short-Term Investments | 608.50M | 712.52M | 942.92M | 1.74B | 2.30B | 2.46B |
| Total Debt | 322.28M | 253.40M | 221.13M | 131.88M | 7.63M | 9.13M |
| Total Liabilities | 614.64M | 644.11M | 397.88M | 678.86M | 144.48M | 67.99M |
| Stockholders Equity | 1.97B | 2.03B | 2.27B | 2.64B | 3.02B | 2.81B |
Cash Flow | ||||||
| Free Cash Flow | -153.20M | -285.29M | -899.67M | -506.61M | -506.11M | -206.35M |
| Operating Cash Flow | 36.21M | -5.18M | -583.49M | -376.20M | -436.37M | -181.10M |
| Investing Cash Flow | -84.06M | -140.38M | -386.29M | -463.28M | -424.75M | -12.48M |
| Financing Cash Flow | 12.05M | 10.38M | 85.11M | 117.44M | 741.98M | 2.34B |
Peijia Medical Ltd. Technical Analysis
Peijia Medical Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$9.75B | 36.61 | 5.55% | 0.77% | -12.57% | -30.70% | |
| ― | HK$7.81B | 46.11 | 4.99% | 0.46% | 35.01% | 483.73% | |
| ― | HK$6.93B | 31.33 | 11.79% | 1.35% | -5.18% | -9.69% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$2.99B | 563.64 | 0.22% | ― | -4.38% | ― | |
| ― | €3.93B | -16.01 | -11.20% | ― | 29.25% | 9.02% | |
| ― | $23.85B | ― | -24.77% | ― | -1.04% | 60.66% |
Peijia Medical Ltd. Corporate Events
Peijia Medical Ltd. announced that its registration application for the GeminiOne® transcatheter edge-to-edge repair system has been accepted by the National Medical Products Administration of China. This novel device, featuring a unique sliding groove mechanism and other innovations, aims to simplify procedures and accommodate a wider range of anatomical variations, potentially enhancing the company’s market position in the medical device industry.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. announced the successful enrollment of the first patient in a multi-center registration clinical trial for its ReachTactile™ robotic-assisted TAVR system. This trial aims to evaluate the safety and efficacy of the system, which features a mobile, modular design and real-time tactile feedback for precise navigation in complex vascular conditions. The outcome of this trial will support the company’s future registration application with the National Medical Products Administration, potentially enhancing its market position in the medical technology industry.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Limited announced the successful first implantation in the first-in-man clinical trial of the Sutra Hemi-valve Transcatheter Mitral Valve Repair System, a key product of Sutra Medical, Inc. The procedure, performed on a high-risk patient with severe mitral regurgitation at Waikato Hospital in New Zealand, marks a significant milestone in the development of innovative cardiac treatments. This advancement highlights Peijia Medical’s strategic investment in cutting-edge medical technologies, potentially enhancing its market position and offering new solutions for patients with limited treatment options.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. reported a 17.3% increase in revenue for the first half of 2025, driven by robust sales growth in its TAVR and neurointerventional businesses. The company achieved significant market share gains in China’s transfemoral TAVR market and launched new premium products, contributing to a 24.0% rise in TAVR-related sales. Neurointerventional product sales also grew by 12.2%, supported by market penetration of existing products and the introduction of the YonFlow Flow Diverting Stent. Operational efficiency improvements led to a 42.4% increase in the Neurointerventional Business segment profit and a narrowing of losses in the Transcatheter Valve Therapeutic Business. Overall, Peijia Medical’s strategic initiatives and market education efforts have strengthened its position as a leading TAVR brand in China.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation for the payment of an interim dividend, highlighting the company’s ongoing financial activities and potential shareholder returns.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
Peijia Medical Ltd. announced unaudited operating statistics for the first half of 2025, highlighting a revenue increase driven by market share gains in the TAVR sector and the introduction of premium products. The company expanded its TAVR portfolio into over 70 new hospitals, achieving significant growth in implantations. The launch of new neurointerventional products also contributed to robust performance, indicating strong market positioning and potential future growth.
The most recent analyst rating on (HK:9996) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.